Ivermectin and Mebendazole for Brain Cancer: A Case Series of 121 Case Reports (April 2026 Update)

Abstract

Glioblastoma and other high-grade brain tumors remain among the most lethal malignancies, characterized by aggressive growth, therapeutic resistance, and near-universal recurrence despite multimodal standard-of-care treatment. In recent years, drug repurposing has emerged as a promising strategy to accelerate the identification of novel anticancer therapies. Among these, the antiparasitic agents ivermectin and mebendazole have attracted increasing attention due to their demonstrated anticancer activity in preclinical models, including effects on cancer stem cells, tumor metabolism, microtubule dynamics, and signaling pathways relevant to glioma progression.

This article presents a compilation of over 100 real-world case reports compiled between 2019 and 2026, involving patients with glioblastoma, astrocytoma, and other intracranial tumors who incorporated ivermectin and/or mebendazole into their treatment regimens. Reported outcomes include tumor stabilization, radiographic regression, delayed recurrence, and prolonged survival, often in patients with poor prognostic features. These observations are contextualized alongside mechanistic evidence and emerging translational research, including studies suggesting blood–brain barrier penetration and potential synergistic effects with metabolic and adjunctive therapies.

While these findings are hypothesis-generating and highlight a potentially transformative therapeutic avenue, they remain predominantly anecdotal and observational. Robust prospective clinical trials are required to validate efficacy, optimize dosing strategies, and define safety profiles. This review underscores both the promise and the limitations of repurposed antiparasitic agents in neuro-oncology, advocating for rigorous investigation within an evidence-based framework.

---

Introduction

Primary brain tumors, particularly glioblastoma multiforme* (GBM), represent one of the most challenging domains in modern oncology. Despite advances in surgical resection, radiotherapy, and chemotherapy—most notably temozolomide—median overall survival for GBM remains approximately 12–18 months, with recurrence considered inevitable in the majority of patients. The persistence of treatment-resistant cancer stem cells, intratumoral heterogeneity, and the protective constraints of the blood–brain barrier contribute to poor therapeutic outcomes and highlight the urgent need for novel treatment strategies.

Drug repurposing has gained traction as a pragmatic and cost-effective approach to accelerate cancer drug discovery. By leveraging existing pharmacokinetic and safety data, repurposed agents can bypass early-stage development barriers. Within this context, ivermectin and mebendazole—widely used antiparasitic medications—have emerged as candidates of interest due to accumulating preclinical evidence demonstrating anticancer properties. These include inhibition of proliferation pathways, disruption of microtubule function, induction of apoptosis, and targeting of cancer stem cell populations implicated in glioma recurrence.

Notably, both agents have shown the ability to penetrate or influence the central nervous system, a critical requirement for effective brain tumor therapeutics. Mebendazole, a benzimidazole compound, has demonstrated activity against glioma models, while ivermectin has been associated with modulation of signaling pathways such as WNT/β-catenin and PI3K/Akt, which are frequently dysregulated in GBM.

Drawing from a surge of compelling success stories documented from 2019 (METRICS study) to 2026, this article explores more than 100 real-world case reports of patients achieving remarkable outcomes, such as tumor stabilization, shrinkage, and even remission, when incorporating high-dose ivermectin and mebendazole into their regimens—often alongside or in lieu of conventional treatments. These reports span diverse patient populations, including both adult and pediatric cases, and frequently involve individuals with advanced or treatment-refractory disease.

However, the interpretation of such evidence requires caution. Case reports and observational datasets are inherently limited by selection bias, lack of controls, and variability in treatment regimens. Moreover, despite promising preclinical signals, clinical validation remains sparse, and leading oncology bodies continue to regard these approaches as investigational.

In this context, this article aims to critically examine the emerging role of ivermectin and mebendazole in brain cancer management by integrating mechanistic insights, preclinical data, and real-world case observations. By doing so, it seeks to delineate the boundary between signal and speculation, while outlining priorities for future clinical research in this rapidly evolving field.

Note: Glioblastoma is not categorized by stages. Brain cancers are “graded” instead of “staged;” grades indicate how the cancer cells appear under a microscope, as well as how likely they are to reproduce. Like stages, brain cancer grades range from 1 to 4. The higher the grade, the more aggressive the cancer. However, glioblastomas are classified as grade 4 brain cancer. That’s because this type of cancer is an aggressive form of astrocytoma.

Contents:

• Case 115: 12 year old New York boy with ASTROCYTOMA
• Case 114: 15 year old Canadian boy with high grade GLIOMA
• Case 113: 47 year old man in TURKEY with Glioblastoma
• Case 112: 69 year old Kentucky man with Glioblastoma
• Case 111: 57 year old Quebec woman with Glioblastoma
• Case 110: 50 year old woman with Glioblastoma
• Case 109: 55 year old New Jersey woman with GLIOBLASTOMA
• Case 108: 7 year old boy in Siberia, Russia, with Cervicomedullary Ganglioglioma
• Case 107: 35 year old Canadian woman with Grade 4 ASTROCYTOMA
• Case 106: 5 year old Boy from SWITZERLAND with a brain tumor (Diffuse Intrinsic Pontine Glioma, or DIPG)
• Case 105: 61 year old Kentucky woman with Oliogodendroglioma (Grade 2)
• Case 104: 57 year old Florida man with Glioblastoma Brain Tumor
• Case 103: 51 year old Toronto man with Glioblastoma
• Case 102: 66 year old Ontario man with Glioblastoma (unmethylated)*
• Case 101: 74 year old Canadian man with Glioblastoma
• Case 100: Brain Cancer Testimonial from Brazil
• Case 99: 36 year old California woman with multifocal Grade 4 Astrocytoma
• Case 98: Stage 4 brain cancer terminal and on radiation and chemo
• Case 97: 41 year old Canadian man with Grade 3 Oligodendroglioma Brain Cancer
• Case 96: Male with Glioblastoma (Oct 2024)
• Case Series 1 - 95 (METRICS study)

Case Presentations (121 cases)

Case 121: 35 year old Canadian woman with 6cm Glioblastoma brain tumor

Dr William Makis posted on X.com (April 2026):

IVERMECTIN and MEBENDAZOLE Testimonial - 35 year old Canadian woman with 6cm Glioblastoma brain tumor reports after 10 months: No regrowth! STORY 35 year old Canadian woman with Glioblastoma 6cm tumor with surgery Nov.4, 2024 and 90% of tumor resected. This was followed by chemo. In Feb.2025 she started Ivermectin and Mebendazole, taken alongside chemo Results after 10 months: No regrowth, stable brain MRI!! This is a complete game changer for brain tumors, there is nothing as promising as the combination of Ivermectin and Mebendazole!

Although there are already 2 human Brain Cancer Clinical Trials with Mebendazole, we will create the first combination Trial with Ivermectin.

Case 120: 71 year old COLORADO Woman with GLIOBLASTOMA

Dr William Makis posted on X.com (April 2026):

IVERMECTIN and MEBENDAZOLE Testimonial - 71 year old COLORADO Woman with GLIOBLASTOMA reports after 6 months: no growth, no recurrence! No chemo needed! Ivermectin Glioblastoma success stories are some of my most favorite! STORY: 71 year old COLORADO Woman with Glioblastoma. In July 2025 she started: Ivermectin and Mebendazole.

Results after 6 months: No tumor growth, no recurrence. No more chemo needed!

Case 119: 69 year old woman in SCOTLAND with a Glioblastoma IDH1 wildtype

Dr William Makis posted on makisw.substack.com (March 2026):

IVERMECTIN (with DMSO), FENBENDAZOLE and MEBENDAZOLE Testimonial - 69 year old woman in SCOTLAND with a Glioblastoma IDH1 wildtype reports after 6 months: Tumor shrinking! STORY: 69 year old woman in SCOTLAND with a Glioblastoma IDH1-wildtype In September 2025, she started:

• Ivermectin 60-72mg/day with DMSO
• Fenbendazole 1332mg/day with MCT Oil and Extra Virgin Olive Oil

Results after 6 months: “There has been a reduction in both glioblastoma and the oedema (the infection/ resulted from the hospital-acquired brain infection). The Oncologist was very pleased, said I should continue what I am doing and asked if I would provide them with what I am using, which I am wary of doing” KEY POINT: Fenbendazole crosses the Blood Brain Barrier.

Important update: Most of the X.com (formerly Twitter) links from Dr William Makis now appear to be broken or inaccessible. This may be related to legal actions or regulatory proceedings involving Canadian authorities, although the exact reason for the link removals is not publicly clear. As a result, many of the original posts that were previously shared or cited on X.com are no longer available through their original links. The vast majority of the case reports, testimonials, and cancer-related discussions originally shared on X are mirrored (and actively updated) on his Substack: makisw.substack.com (published as "COVID Intel - by William Makis" / McGill Medicine branding).

Case 118: 34 year old South Carolina man with GLIOBLASTOMA IDH-Wildtype

Dr William Makis posted on X.com (March 2026):

IVERMECTIN, MEBENDAZOLE, CBD Oil Testimonial - 34 year old South Carolina man with GLIOBLASTOMA IDH-Wildtype reports after 3 months: Tumor shrinking! Glioblastoma success stories are AMAZING! These are very difficult tumors to deal with... STORY: 34 year old South Carolina man with GLIOBLASTOMA IDH-Wildtype In November 2025 he started:

• Ivermectin 1.5mg/kg/day
• Mebendazole 1500mg/day
• CBD Oil 100mg/day

From patient's family: "Glioblastoma is showing some improvement" "Recent imaging shows improvement—reduced inflammation, around surgical cavity and existing midline tumor area appears less “angry”. "Oncologist said XXX had a “good” looking scan this time" KEY POINT: It is very difficult to get Glioblastomas to shrink! To have success with Brain cancers is a real test.

Case 117: 24 year old NEW ZEALAND Man with Astrocytoma Grade 3

Dr William Makis posted on X.com (February 2026):

IVERMECTIN and MEBENDAZOLE Testimonial - 24 year old NEW ZEALAND Man with Astrocytoma Grade 3 reports after 10 months: No growth!

STORY: 24 year old NEW ZEALAND Man with Astrocytoma In May 2025 he started:

• Ivermectin 108mg/day
• Mebendazole 1500mg/day (from July)

Results after 10 months No growth of tumor!! In Brain tumors, especially aggressive ones like Glioblastoma and Astrocytoma, victory is to completely halt the growth of these tumors.

Case 116: 50 year old INDIANA Man with Glioblastoma

Dr William Makis posted on X.com (February 2026):

IVERMECTIN and MEBENDAZOLE Testimonial - 50 year old INDIANA Man with Glioblastoma reports after 10 months: No residual disease, No recurrence.

A Glioblastoma Success story! (No one has these) 50 year old INDIANA Man with Glioblastoma diagnosed and operated on in Dec.2024, with Radiation and TMZ chemo starting in Jan.2025 In April 2025 he started:

• Ivermectin 0.5mg/kg/day 
• Mebendazole 1500mg/day 
• CBD Oil 100mg/day

RESULTS: 10 months later, there is no growth and no recurrence! KEY POINTS: With Glioblastomas, we have been able to eliminate residual disease and recurrences in most cases, which is a game changer with this disease.

Case 115: 12 year old New York boy with ASTROCYTOMA

Dr William Makis posted on X.com (December 2025):

IVERMECTIN, MEBENDAZOLE and FENBENDAZOLE Testimonial - 12 year old New York boy with ASTROCYTOMA reports after 6 months - 40% tumor shrinkage!

An incredible Child Brain Cancer success story! 

12 year old New York boy with ASTROCYTOMA In June 2025 he started: Ivermectin, Mebendazole, Fenbendazole. Oncologist prescribed: Koselugo (Selumetinib) Result after 6 months: 40% tumor shrinkage.

Case 114: 15 year old Canadian boy with high grade GLIOMA

Dr William Makis shared on X.com (December 2025):

IVERMECTIN and MEBENDAZOLE Testimonial - 15 year old Canadian boy with high grade GLIOMA after 2 Pfizer COVID-19 mRNA Vaccines, reports after 2 months - up to 70% tumor shrinkage!

Remember...those who attack me and my work also attack children with cancer. Shame on them! 15 year old Canadian boy with high grade GLIOMA with a history of 2 Pfizer COVID-19 mRNA Vaccines (take a moment to read that again) Early Aug.2025 - diagnosed with brain tumors and had surgical resection (5-10% of tumor left behind) Sep.2025 - Radiation Therapy (30 rounds) In August 2025 he started: Ivermectin 36mg + Fenbendazole 444mg x 2 weeks Ivermectin 36mg + Mebendazole 444mg x 3 weeks Ivermectin 36mg + Mebendazole 700mg x 2 weeks Makis Protocol: Ivermectin 48mg + Mebendazole 1500mg x 2 months From the parents: "We were told it is a very good result with the 2 remaining tumors shrinking significantly. Approximately 65-70%" KEY POINTS: Johns Hopkins has a 2021 patent on Mebendazole for treatment of Cancer, specifically Glioblastoma Notice that the 15 year old boy was taking Ivermectin and Mebendazole during the entirety of his 30 Radiation treatments (!!) He benefited from Radiosensitization of his tumors by Ivermectin and Mebendazole! There are two Clinical Trials with Mebendazole and children with Cancer: NCT02644291 NCT01837862

Case 113: 47 year old man in TURKEY with Glioblastoma

Dr William Makis shared on X.com (December 2025):

IVERMECTIN, MEBENDAZOLE, FENBENDAZOLE Testimonial - 47 year old man in TURKEY with Glioblastoma reports after 9 months - clean scans!! I got an invitation to Turkey.

A success story from Turkey and I got an invitation to go for the summer! STORY: 47 year old man in TURKEY with Glioblastoma In Dec.2024 he did an operation that got 98% of the tumor. Had chemo and radiotherapy in Jan-Feb. 2025. In March 2025, he started:

• Ivermectin 70mg 
• Fenbendazole 888mg 
• Mebendazole 1000mg

His September 2025 MRI was CLEAN. That's 9 months after surgery that left 2% of the tumor behind. No recurrence. No residual tumor. What an incredible story!! The most difficult thing about Glioblastoma are the recurrences, these tumors very often grow back and grow back rapidly. I believe a combination of Ivermectin and Mebendazole (and perhaps Fenbendazole as well) can stop Glioblastoma recurrences. This would be a complete game changer for Brain Tumors! Including in children! We now have a couple of dozen such successes and all that remains is to see how durable this “Cancer Free” and "Recurrence Free" effect is over the long term.

Case 112: 69 year old Kentucky man with Glioblastoma

Dr William Makis shared on X.com (December 2025):

IVERMECTIN and MEBENDAZOLE Testimonial - 69 year old Kentucky man with Glioblastoma reports after being on Protocol for 12 months.

A 12 month Glioblastoma success story!! (Oncologists don't have these) STORY: 69 year old Kentucky man with a 4.5cm Glioblastoma In October 2024 he Started: Ivermectin 2mg/kg/day Mebendazole 1500mg/day CBD Oil 75mg/day In January 2025 he started: Ivermectin 2mg/kg/day Mebendazole 2000mg/day Fenbendazole 1000mg/day CBD Oil 100mg/day His brain tumor has consistently shrunk over the past 12 months!! The MRIs are read right to left "Doc was very happy and asked me to take the treatments exactly how I have been doing" Glioblastoma is not easy to deal with so to see a shrinking Glioblastoma over a course of 12 months is incredible!!

Case 111: 57 year old Quebec woman with Glioblastoma

Dr William Makis shared on X.com (November 2025):

IVERMECTIN and MEBENDAZOLE Testimonial - 57 year old Quebec woman diagnosed with Glioblastoma in Dec.2024, reports after 8 months.

A Canadian Glioblastoma success story? STORY: 57 year old Canadian woman diagnosed with Glioblastoma in Dec.2024, after 3 COVID-19 mRNA Vaccines (1 Moderna, 2 Pfizer May 2021 to Jan.2022) Had chemo & radiation January / February 2025 In March 2025 she started:

• Ivermectin 1.5mg/kg/day
• Mebendazole 1500mg/day (sometimes takes Fenbendazole 1500mg/day)

Results after 8 months: NO RECURRENCE! "More good news! My oncologist had me undergo another MRI, and once again, there's no progression."

Case 110: 50 year old woman with Glioblastoma

Dr William Makis shared on X.com (November 2025):

IVERMECTIN and MEBENDAZOLE (and Dr. Thomas Seyfried) Testimonial - 50 year old woman with Glioblastoma shares her story after given 7 months to live - 16 months later, 4 MRIs, NO RECURRENCE.

"My wife who is 50 years old, diagnosed with a glioblastoma multiforme brain tumor in April 2024 had a 6 hour surgery and given 7 months to live" When you have Glioblastoma and your Oncologist gives you 7 months to live, there is very little hope there. Except... "2 months of radiation and chemo...she couldn't handle the radiation and chemo and quit the treatment half way through" (June 2024) "We found ivermectin and mebendazole protocol as well as Dr. Thomas Seyfried's work with ketogenic diets". "The last 4 MRIs have been clear and no growth. She is feeling great with no deficits" Let all this sink in. 16 months on Ivermectin and Mebendazole. Was supposed to be dead after 7 months. Instead, she has 4 clear MRIs, no growth. No chemo. No radiation. No Oncology treatments. Go ahead, tell me again how Oncologists can justify NOT OFFERING this to dying cancer patients. If this cancer patient relied on her Oncologist, she would have been DEAD 9 months ago!!!

Case 109: 55 year old New Jersey woman with GLIOBLASTOMA

Dr William Makis shared on X.com (November 2025):

IVERMECTIN and MEBENDAZOLE Testimonial - 55 year old New Jersey woman who developed GLIOBLASTOMA after 2 Pfizer Vaccines reports after 3 months - 46% tumor shrinkage!

A Glioblastoma shrinks almost 50% with Ivermectin and Mebendazole!

STORY: 55 year old New Jersey woman who developed GLIOBLASTOMA after 2 Pfizer Vaccines (very likely Turbo Cancer) In late June / early July 2025 she started:

• Ivermectin 1.5mg/kg/day
• Fenbendazole 1776mg/day (then switched to Mebendazole 1500mg/day)

Results after 3.5 months: 46% tumor shrinkage! Radiologists called it "mildly decreased in size". This is a fantastic result. With brain cancers, we're usually very happy to see tumors stop growing or stop them from coming back. But almost 50% brain tumor shrinkage over 3 months is incredible!! Remember, Johns Hopkins has a 2021 PATENT on Mebendazole for the treatment of Glioblastoma!! They know something mainstream Oncologists don't!

Case 108: 7 year old boy in Siberia, Russia, with Cervicomedullary Ganglioglioma

Dr William Makis shared on X.com (November 2025):

IVERMECTIN and MEBENDAZOLE Testimonial - 7 year old boy in Siberia, Russia, with Cervicomedullary Ganglioglioma reports after 3 months

You never think you're going to be able to help a 7 year old boy in the middle of Siberia, Russia. STORY: 7 year old boy in Siberia, Russia, with Cervicomedullary Ganglioglioma (a rare brain tumor at the junction of the brainstem and spinal cord, composed of both neuronal and glial cells) In early August 2025 he started:

• Ivermectin 1mg/kg/day
• Mebendazole 1000mg/day

Result: “Ivermectin + Mebendazole gave us our son back” Stable tumor In Pediatric tumors especially brain tumors, halting tumor growth is a success, as is any clinical improvement. These are very difficult tumors.

Case 107: 35 year old Canadian woman with Grade 4 ASTROCYTOMA

Dr William Makis shared on X.com (November 2025):

IVERMECTIN and MEBENDAZOLE Testimonial - 35 year old Canadian woman with Grade 4 ASTROCYTOMA reports after 7 months. No recurrence!

This is a Game Changer with Brain Tumors!
35 year old Canadian woman with Grade 4 ASTROCYTOMA

In February 2025 she started:

Ivermectin 1.5mg/kg/day
Mebendazole 1500mg/day

MRI Report after 7 months:

“No acute change at site of previously debulked left temporal tumor”

“No evidence of disease progression”

From patient:
“we are very happy!”

Imagine if we could stop aggressive brain tumors dead in their tracks! Stop them from coming back!

I believe it can be done.

This is one of MANY areas to research with allocated government funding. Florida leads the way...

Case 106: 5 year old Boy from SWITZERLAND with a brain tumor (Diffuse Intrinsic Pontine Glioma, or DIPG)

Dr William Makis shared on X/Twitter (November 2025):

IVERMECTIN, MEBENDAZOLE and FENBENDAZOLE Testimonial - 5 year old Boy from SWITZERLAND with a brain tumor (Diffuse Intrinsic Pontine Glioma, or DIPG) reports after 4 months with tumor shrinkage!

Pediatric cancer cases are hard but pediatric cancer success stories are the best.

STORY:
5 year old boy from SWITZERLAND with a brain tumor (Diffuse Intrinsic Pontine Glioma, or DIPG)

In early June they started:

• Ivermectin 1mg/kg/day
• Mebendazole 1500mg/day
• Fenbendazole 1500mg/day

With pediatric cases, we are always cautiously optimistic and pray for our little angels.

From Dad:
“the most recent MRI showed that the brainstem tumor has been reduced by 26% compared to the last scan”

With pediatric cases, we are always cautiously optimistic and pray for our little angels.

DIPG is a fast-growing and aggressive type of brain tumor that starts in the part of the brain stem called the pons.

The pons controls many vital functions such as breathing, heart rate, and blood pressure, and the nerves and muscles used in seeing, hearing, walking, talking, and eating.

How many children with cancer are we helping?

We’ve now surpassed 100 kids.

Case 105: 61 year old Kentucky woman with Oliogodendroglioma (Grade 2)

Dr William Makis shared on X/Twitter (October 2025):

IVERMECTIN and FENBENDAZOLE Testimonial - 61 year old Kentucky woman with Oliogodendroglioma (Grade 2) reports brain tumor shrinkage after 5 months!

Very interesting story here! 61 year old Kentucky woman with Oliogodendroglioma (Grade 2) In early May 2025 she started: Ivermectin 36mg/day Fenbendazole 1500mg/day Results after 5 months on MRI: "Mild decrease in hyperintense non-enhancing mass" "She (the Oncologist) was very excited and pleased and didn't expect the tumor to shrink a bit" Of course she didn't. This is a very interesting story because many people falsely claim that Ivermectin and Fenbendazole don't cross the blood brain barrier. Except that's false. They do. Not well, but they do.

Case 104: 57 year old Florida man with Glioblastoma Brain Tumor

Dr William Makis shared on X/Twitter (October 2025):

IVERMECTIN and MEBENDAZOLE Testimonial - 57 year old Florida man with Glioblastoma Brain Tumor gives incredible report after 3 months!

Read it for yourself. 

"I am clear at month 4 and that gives me hope and it will give other people hope"

"Both of my oncologists DID NOT expect this. All my doctors told me I should prepare to die after my surgery in June. They said my diagnosis was very aggressive, and it most certainly would grow back" 

"Most recent MRI shows that the tumor and all signs of cancer are gone"

"One of my oncologists even told me that I should expect to possibly have to go into HOSPICE LATER IN THE FALL if their standard of care did not work"

Read his incredible story. It only takes a few minutes.

Case 103: 51 year old Toronto man with Glioblastoma

Dr William Makis shared on X/Twitter (October 2025):

IVERMECTIN and MEBENDAZOLE Testimonial - 51 year old Toronto man with Glioblastoma reports after 6 months - has tumor shrinkage that baffles Oncologists!

This time, I'm baffling Oncologists in my old home town, Toronto, Canada! And I love it because Toronto doctors are particularly arrogant! STORY: 51 year old Toronto man with Glioblastoma In Late February 2025 he started: Ivermectin 1.5mg/kg/day Mebendazole 1500mg/day After 6 months, his tumor is shrinking but his Oncologists believe it is from Radiation and chemo he finished in October 2024. "since there is progress in tumor shrinkage...they are attributing the shrinkage to the chemo and radiation of last year this time" "We feel that the real shift began once we started your protocol but they are not aware of what we're doing".

Case 102: 66 year old Ontario man with Glioblastoma (unmethylated)*

Dr William Makis shared on X/Twitter (June 2025):

IVERMECTIN and MEBENDAZOLE Testimonial - 66 year old Ontario man with Glioblastoma (unmethylated) reports after 5 months - no recurrence.

A Glioblastoma success story! 66 year old Ontario man with Glioblastoma (unmethylated). For 5 months, the patient was on:

• Ivermectin 168 mg/day
• Mebendazole 1500 mg/day
• Melatonin 500 mg/day

RESULT: No recurrence on follow-up imaging!

Glioblastoma (GBM) is a lethal disease. At least in part, the recurrence of GBM is caused by cancer stem cells (CSCs), which are resistant to chemotherapy. Ivermectin targets and kills Cancer Stem Cells! The question is whether we can completely prevent recurrence of Glioblastoma (unmethylated) over the long term. I believe we can. But we have to prove it with long term studies. That's next.

*Note: Glioblastoma is otherwise known as Stage IV Astrocytoma. Unmethylated glioblastoma refers to a glioblastoma (GBM) tumor where the MGMT promoter is unmethylated, which is a poor prognostic indicator. The unmethylated state means the tumor is resistant to temozolomide (TMZ), a standard chemotherapy drug for GBM, leading to a worse prognosis compared to methylated tumors. Therefore, patients with unmethylated GBM require alternative treatment strategies, such as other chemotherapy, immunotherapy, targeted therapies, or novel approaches like CRISPR-based epigenetic editing, to improve outcomes.

Case 101: 74 year old Canadian man with Glioblastoma

Dr William Makis shared on X/Twitter (June 2025):

IVERMECTIN and MEBENDAZOLE - 74 year old Canadian man with Glioblastoma gives an exciting update after 3 months!

Do you want to hear a brain cancer success story? Of course you do! 74 year old Canadian man with Glioblastoma In early March 2025 we started:

• Ivermectin 1.5mg/kg/day
• Mebendazole 1500mg/day
• CBD Oil 100mg/day

The patient was on this regimen for 3 months (and if you count the Ivermectin and Fenbendazole they started on their own in early February, then 4 months). From the patient: "he recently had his first MRI since chemo and radiation begun - there were no abnormal changes - no abnormalities - no new artifacts Overall, both our family and the oncologists were extremely happy to not see any visible growth or changes." "First off, thank you for your work and services, I have zero doubt that the results would have been different if we didn’t have your guidance." I do believe that Glioblastoma recurrence could be eliminated with a repurposed drug regimen that includes Ivermectin and Mebendazole. Of course, now we have to prove it with long term follow-up and publish it. Remember, this patient was quoted a life expectancy as low as 6 months as Glioblastomas are notorious for recurrence despite best conventional cancer treatment. We are 4 months in and the patient is CANCER FREE.

Case 100: Brain Cancer Testimonial from Brazil

"We applied your protocol plus methylene blue to a friend with brain cancer...started in beginning of February 2025...she is cancer free now!

"Getting more details...story developing.

Ivermectin. Mebendazole. Methylene Blue.

Case 99: 36 year old California woman with multifocal Grade 4 Astrocytoma

Dr William Makis shared on X/Twitter (May 2025):

IVERMECTIN and MEBENDAZOLE Testimonial - 36 year old California woman with multifocal Grade 4 Astrocytoma is now improving after 2 months! I get asked for Brain Cancer stories ALL THE TIME Here is one! (More are coming soon) STORY: 36 year old California woman was diagnosed with multifocal Grade 4 Astrocytoma (7 brain lesions) in January 2025 In late January 2025 we started:

• Ivermectin 1mg/kg/day
• Mebendazole 1500mg/day

RESULTS after 2 months: "We received results of her MRI yesterday...her oncologist informed us that her tumors are at the very least stable and appear to be shrinking" “They were absolutely shocked as they didn’t seem to have much hope for her prior to this as her cancer was aggressively progressing prior to your treatment”

"If you are unsure how big of a role an Ivermectin/Fenbendazole/Mebendazole protocol plays, always look at the reaction of the Oncologists. They rarely hide their shock. Brain tumors are difficult to treat in general, but the Ivermectin & Mebendazole combination is starting to make a huge impact in this area." - Dr William Makis

Case 98: Stage 4 brain cancer terminal and on radiation and chemo

Doverschoice posted on X/Twitter in April 2025:

My mother had the vaccine and one booster stage 4 brain cancer terminal and on radiation and chemo. Have tried to reach out to William for some time to get some help on what to give her!

Dr William replied (April 2025):

Mebendazole, CBD, Ivermectin would be my top 3.

Case 97: 41 year old Canadian man with Grade 3 Oligodendroglioma Brain Cancer

Dr William Makis shared on X/Twitter (Feb 2025):

IVERMECTIN and FENBENDAZOLE Testimonial - 41 year old Canadian man with Grade 3 Oligodendroglioma Brain Cancer opts out of chemo & radiation - doing extremely well! 

STORY: 

41 year old Ontario man had an aggressive Grade 3 Oligodendroglioma that was mostly resected in early June 2024. After surgery, he opted out of chemo and radiation therapy. Sep.2024 MRI showed “residual parenchymal tumoral component” 4.5x4.1x3.6cm.

We started an aggressive Makis Ivermectin Cancer Clinic Protocol: 

• Ivermectin 1mg/kg/day increasing to 2mg/kg/day 
• Fenbendazole 888mg/day

He had a follow-up MRI 3 months later: RESULTS: The Radiologist couldn’t find the residual tumor! From the patient: 

"Thank you so much. I don't know how else to put it. This is not a big deal...its THE deal. A cure for "terminal" brain cancer. The implications are mind-blowing and its sad so few people know about these options." 

"Keep up the good fight please!"

Case 96: Male with Glioblastoma

Case sharing by Michelle Wright (X/Twitter) in October 2024:

The reading of the results has been posted!! There is a whole lot that I DON’T understand, but I can understand enough to see that THERE HAS BEEN IMPROVEMENT!!  I appreciate all of the prayers and well wishes!  For anyone that isn’t up to date- my Dad was diagnosed with Glioblastoma in April of this year. He had completed one full round of chemo and radiation, and at the beginning of August he was not well. I won’t go into detail. However, I had been doing a lot of research and one of the AWESOME pages I found here was @JohnDParody  I went with a protocol that I felt was best and got my Dad started on a journey with Ivermectin and Fenbendazole. He HAS continued his chemo treatments, but I 100% believe it has been that being used in combination with the Ivermectin and Fenben that has gotten him where he is today. I’ve been here, and I’ve watched him improve daily. I do not have pictures of the scans themselves, because they’re not posted on the portal. But if anyone would like to compare it to any of his previous readings, I can get those as well. I’m going to go celebrate with my Dad.

Note:

Although the fenbendazole and mebendazole are very similar in effectiveness at higher doses, Mebendazole has superior brain cancer cell killing at lower loses compared to Fenbendazole. So for Glioblastoma, it’s Mebendazole if you can get it. Otherwise, you can't go wrong with Fenbendazole. It's still almost as good. (source)

Albendazole is also recommended for brain related cancers or brain spread, as it can cross the blood-brain barrier. (source)

Case Series 1 - 95 (METRICS study)

The Care Oncology Clinic in the UK, which is now doing clinical trials on glioblastoma, published their preliminary retrospective data from the METRICS study (NCT02201381) in Frontiers in Pharmacology (2019) about the combination standard treatment and repurposed drugs in 95 patients. 

Full inclusion and exclusion criteria and further methodological details can be found at https://clinicaltrials.gov/ct2/show/NCT02201381:

Subjects will take the following treatments (adjunctive) and have their data collected from their medical records every 3 months.

• Oral Mebendazole 100 mg once a day, for study duration.
• Oral atorvastatin up to 80 mg once a day, for study duration.
• Oral metformin up to 1000 mg once a day, increased to bid if tolerated after 2 weeks, for study duration.
• Oral doxycycline 100 mg once a day, for study duration.

The retrospective analysis consisted of 95 patients with advanced GBM (brain cancer) stage IV (GBM) who attended the clinic between 2013 and 2016.

Simply adding metformin, doxycycline, atorvastatin, and mebendazole in addition to optimal standard of care can increase GBM (Glioblastoma) average survival from 15 to 27 months, almost a doubling.

Are there more case reports? For more Fenbendazole and Ivermectin case series in other cancer types, check out 'Ivermectin, Fenbendazole, and Mebendazole Cancer Case Series' (more than 590 case reports).

Discussion

The Care Oncology Clinic’s 4-Drug COC Protocol — comprising Doxycycline, Atorvastatin, Mebendazole, and Metformin — represents a strong foundational approach to metabolic cancer therapy. In the METRICS trial, adding this protocol to standard of care in Glioblastoma was associated with nearly a one-year increase in survival.

Despite these promising results, resistance to the COC Protocol has been reported as well. The core problem lies in the nature of Cancer Stem Cells (CSCs): these cells are remarkably adaptable. When placed under primarily metabolic pressure, CSCs exploit alternative fuel sources and, given enough time, appear to reliably escape any single-axis metabolic attack.

Building a more powerful, resistance-prevention protocol requires a broader strategy — one that targets far more than cancer’s metabolism alone.

Cancer cells can evade treatment by switching fuel sources — shifting from glucose to glutamine or even lipid metabolism. The COC 4-Drug Protocol has additional drawbacks worth noting. Doxycycline, at standard dose, disrupts the gut microbiome, reducing the effectiveness of agents like Keytruda and Paclitaxel. Atorvastatin carries known risks of liver and muscle toxicity.

The RESET-5 protocol (Sulforaphane, Aged Garlic Extract, Mebendazole, Ivermectin, Metformin) proposed by Dr Justus Hope is a comprehensive, multi-targeted approach designed to eradicate cancer stem cells (CSCs), reverse chemo-resistance, and restore immune competence.

The COC protocol (Care Oncology Clinic) relies on Doxycycline and Atorvastatin, which act as metabolic suppressors but have only limited activity to block the fundamental CSC pathways (Wnt, Notch, Hedgehog) that allow cancer stem cells to survive and mutate. In contrast, the RESET-5 protocol targets these crucial pathways more directly.

The SAC component of AGE (Aged Garlic Extract) achieves near 95 to 98% bioavailability for its water-soluble organosulfur, while properly formulated SFN achieves up to 70 to 80% bioavailability. This provides profound systemic saturation and continuous CSC suppression that the moderately bioavailable Metformin (~55%) and standard Doxycycline cannot match.

As demonstrated in the above scatter chart, Sulforaphane (SFN) and Ivermectin provide substantial CSC inhibition. Ivermectin significantly impairs P-glycoprotein efflux pumps—the primary mechanism tumors use to spit out chemotherapy—while SFN inhibits HDACs, leading to increased histone acetylation, which opens chromatin and allows re-expression of silenced genes.

A critical flaw of the COC protocol is the use of Doxycycline, a broad-spectrum antibiotic that induces severe gut dysbiosis and destroys the microbiome necessary for natural immune surveillance.

The RESET-5 protocol does not contain an antibiotic. SFN and AGE act as powerful, targeted prebiotics that significantly increase populations of Lactobacillus, Bifidobacterium, and Akkermansia.

Multiple high-impact studies have shown that patients with a diverse, favorable gut microbiome experience substantially better response rates and longer survival on PD-1/PD-L1 therapies compared to those with antibiotic-induced dysbiosis.

This native cultivation ensures the gut-immune axis is robustly activated, significantly priming the immune system for CD8+ T-cell infiltration and increasing the efficacy of standard immunotherapies like Keytruda. The microbiome effect is one of the most consistent predictors of PD-1 success across studies.

Atorvastatin carries significant risks of hepatotoxicity and myopathy. Long-term Doxycycline suppresses bone marrow function and strains the kidneys.

The RESET-5 protocol replaces these with highly tolerated phytocompounds and anthelmintics.

SFN and AGE actively protect the liver and bone marrow from chemotherapy-induced toxicity by neutralizing systemic free radicals. Mebendazole and Ivermectin have extensive safety records allowing for continuous use, even in elderly or renally compromised patients.

For brain cancers like Glioblastoma, Ivermectin, SFN, and Mebendazole are highly lipophilic and easily cross the blood-brain barrier. Once inside the brain, they halt tubulin formation and epigenetically reset the neurological stem cells responsible for disease recurrence.

Most berberine and curcumin supplements have low oral bioavailability. UltraCur Curcumin Complex and
Pure Encapsulations Berberine UltraSorb are specially formulated for optimal absorption.

Australian doctor Professor Richard Scolyer and the Moderna mRNA Cancer Vaccine Update

Dr William Makis posted a related comment on X/Twitter (Mar 2026):

Australian doctor Professor Richard Scolyer confirms the Moderna mRNA Cancer Vaccine does NOT WORK! Famous Australian Dr. Richard Scolyer developed an aggressive brain tumor, Glioblastoma after taking multiple COVID-19 mRNA Vaccines due to Australia's draconian mandates, to keep his job. After he was diagnosed with Glioblastoma, he did not pursue the top repurposed drugs for Glioblastoma: Mebendazole and Ivermectin (Johns Hopkins has a patent on Mebendazole for treating Glioblastoma). Instead, he volunteered to test Moderna's new mRNA Cancer Vaccine mRNA-4359, which doesn't work, although they are still pushing forward with Phase III trials by mixing it with Keytruda. Richard Scolyer has just admitted online that his Glioblastoma is progressing, despite taking multiple injections of Moderna's mRNA-4359 Cancer Vaccine for the past year. I predicted this EXACT outcome on my substack last year. It's very sad, that he won't try Mebendazole which is patented for his disease, or Ivermectin.

Dr William Makis posted a related comment on X/Twitter (Apr 2026):

It is now well established that Moderna mRNA-4157 Cancer Vaccine (combined with Keytruda) doesn't work. Moderna's own Clinical Trial data shows it doesn't work and famous Australian Cancer Researcher

@ProfRAScolyer

also confirmed it doesn't work, as his Glioblastoma brain tumor progressed after treatment with several Moderna mRNA-4157 injections While I would love to see the data behind this Russian "personalized mRNA Cancer Vaccine", it is highly improbable that mRNA technology in any iteration would actually work in Cancer. mRNA technology has too many fatal flaws and is currently unfit for human use. Moderna's version involves 9 injections of mRNA and 18 injections of Keytruda. That's a total of 27 injections of a treatment that does virtually nothing.

Alex Kalogeropoulos posted a related comment on X/Twitter (Apr 2026):

There is a lot of nuance to this - depending on the molecular profile of the tumor, chemo (usually temodar) can be less effective. Consequently, there are certain molecular makeups of some tumors that make temodar effective against them, but they also have a much higher risk to eventually hypermutate because of temodar treatment down the line - it’s a double edged sword. Mebendazole makes the most sense for glioma as it has the best brain penetrance compared to ivermectin and fenbendazole. You need to make sure you get Polymorph C Mebendazole (not A or B) and the dose needs to be pretty high about 75mg/kg a day. 

Best bet is if you can get a doctor to write a script for it and get it compounded by a compounding pharmacy that can give you a COA showing Polymorph C purity. Polymorph C Mebendazole is what the Johns Hopkins trial used.

Conclusion

In conclusion, the array of more than 100 compelling case reports from 2025 and 2026, primarily shared by Dr. William Makis and the METRICS study, illuminates the transformative potential of ivermectin and mebendazole as repurposed adjunctive therapies for aggressive brain cancers such as glioblastoma multiforme and astrocytoma—conditions notorious for their resistance to standard treatments and high recurrence rates.

These antiparasitic agents, often administered at high doses (e.g., ivermectin 1-2 mg/kg/day and mebendazole 1500 mg/day) alongside chemotherapy, radiation, or supportive elements like CBD and melatonin, have demonstrated remarkable abilities to target cancer stem cells, stabilize tumors, induce shrinkage, and achieve sustained remission in patients facing dire prognoses. Protocols inspired by these successes, including alternatives like fenbendazole or albendazole for enhanced blood-brain barrier penetration, underscore a multifaceted approach that complements conventional care and offers renewed hope where options were once limited. 

Nevertheless, while these anecdotal triumphs—backed by MRI evidence and oncologist astonishment—signal a paradigm shift in brain cancer management, they remain observational and demand robust, long-term clinical trials to confirm efficacy, safety, and optimal integration. That said, it may take years before these anti-cancer agents get into mainstream medical journals, as bold results often trigger powerful pushback. The biggest confirmation may not come from top journals but from a grassroots movement of patients and doctors who have proven results.

Patients and caregivers are encouraged to collaborate closely with healthcare experts to tailor these strategies, fostering informed, personalized paths toward overcoming this formidable disease.

Important Disclaimers:

• Statements on this website have not been evaluated by the Food and Drug Administration. The contents of this website is for educational and informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis or treatment.
• Please do not consider this guide as personal medical advice, but as a recommendation for use by professional providers. Consult with your doctor and discuss with her/him. Our aim here isn't to replace your doctors' advice. It is intended as a sharing of knowledge and information. Do take note that cancer is a continuous struggle between the immune system and the cancer cells. Cancer treatments are meant to assist the immune system in this battle. Any potential treatment—whether conventional or complementary—must be evaluated on a case-by-case basis, with careful consideration of the benefit-risk ratio to ensure both safety and effectiveness.
• The case reports presented reflect the real-life experiences and opinions of other readers or users of the website. The experiences of those readers or users are personal to those particular readers/users and may not necessarily be representative of all readers/users. We do not claim, and you should not assume, that all other readers/users will have the same experiences. Do you own research, consult with relevant medical professionals before attempting to self-treat for any condition.
• Cancer treatment should be part of a multi-modal approach in order to provide the best possible outcome. Diet and lifestyle changes are meant to run alongside conventional treatment. They are complementary, not alternative. 
• Cancer care is a team effort with the patient at the centre. Care should be supervised and coordinated by a primary healthcare provider. Patients with cancer should consult with their regular oncologist as well as an integrative provider/oncologist, in addition to their primary care provider and the supporting nurses, dietitians and other allied healthcare professionals.
• While the term 'alternative' might imply opposition to conventional oncology, we prefer 'complementary,' 'integrated,' or 'holistic.' These terms better reflect the role of these strategies as part of a personalized value-added menu of strategies, ensuring the most effective and safe solutions for patients.
• Integrating a repurposed drug doesn't mean rejecting modern medicine — It enhances it and offers a more comprehensive approach to wellness and healing. By combining conventional cancer management with root-cause resolution, this model creates a path to sustained recovery and resilience.

References: 

1. Ivermectin, Fenbendazole, and Mebendazole Cancer Case Series (more than 700 case reports).
2. A Glioblastoma Survivor Story | Dr Justus Hope
3. Successful application of dietary ketogenic metabolic therapy in patients with glioblastoma: a clinical study (2025)
4. Intranasal Nano-Ivermectin Shrinks Brain Tumors by 70% Without Toxicity (ACS Biomaterials Science & Engineering 2025)
5. The Effect of Integrative Naturopathic Oncology Including Modulated Electrohyperthermia on Survival Outcome among Glioblastoma Multiforme Patients: A Retrospective Study (N=73 stage 4 Glioblastoma) (Integrative Cancer Therapies 2025)
6. Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle (Nature 2021)
7. The therapeutic potential of repurposed mebendazole, alone and in synergistic combination with ONC201, in the treatment of diffuse midline glioma (AM J Cancer Res 2025)
8. Mebendazole in Glioma Brain Cancer Model - 2025 Johns Hopkins Study (Neuro-Oncology Advances 2025)
9. Methylene Blue in Glioblastoma (Brain Cancer)
10. Bioshield Shows Sustained Early Promise in Recurrent Brain Cancer: Initial 100% Disease Control in Pilot Cohort, with Ongoing Trials - Dr. Patrick Soon-Shiong